Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMEA Refines Post-Market Renewal Requirements To One Five-Year Review

Executive Summary

The European Medicines Agency will require all products to have one review five years after marketing authorization, effective Nov. 20, 2005

You may also be interested in...



EU Drug Applications Will Need Pharmacovigilance Plans In 2005

Pharmaceutical drug marketing applications to the European Medicines Agency will require a pharmacovigilance plan beginning in November 2005

EU Drug Applications Will Need Pharmacovigilance Plans In 2005

Pharmaceutical drug marketing applications to the European Medicines Agency will require a pharmacovigilance plan beginning in November 2005

Drug Safety Changes Should Await IoM, HHS Secretary Tells Congress

HHS Secretary Michael Leavitt is urging Congress to be patient in considering potential changes to FDA's regulation of drug safety

Topics

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel